Clinical Experience in the Treatment of Dermatomycoses with Flutrimazole
V. Semrádová 1; J. Dobešová 2; H. Duchková 3; V. Koudelková 4; I. Kuklová 5
Dermatovenerologická klinika FN U sv. Anny v Brně, přednostka prof. MUDr. V. Semrádová, CSc. 2Dermatovenerologická klinika FN Olomouc přednosta doc. MUDr. M. Buček, CSc. 3Dermatologické odd. Masarykovy nemocnice Ústí nad Labem prim. MUDr. H. Duchková, DrS
Čes-slov Derm, , 2004, No. 4, p. 137-140
The aim of the work was to evaluate the results of dermatomycoses treatment with new imidazoleagent - flutrimazole and to verify its clinical efficacy and tolerability in the form of 1% cream(Micetal®) applied once or twice a day.Methods: 164 patients with dermatomycoses were treated at 5 outpatient dermatovenereologydepartments. Group I included 82 patients (23 males and 55 females) with the mean age of 44.8 years,who applied the cream once a day. Group II included 82 patients as well (38 males and 40 females)with the mean age of 43.1 years, who applied the cream twice a day. Intensity of 8 disease symptomswas evaluated ineach patient at the first examination andafter 2 and4weeks of therapy using a threepoint score.Results: Erythema and scaling were the most prominent clinical symptoms before treatment.After 4 weeks they were reduced by 87% (group I) and 90% (group II) and by 80% (group I) and 83%(group II), respectively. Also pruritus significantly diminished by 88% (group I) and 94% (group II)after therapy.Conclusion: The 1% flutrimazole cream has a very satisfactory clinical efficacy in both, once andtwice daily application schemes.
dermatomycoses - topical therapy - flutrimazole
Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP
Dermatology & STDs
Paediatric dermatology & STDs